Similarly, decreased levels of SPHK1 under chemotherapy were also observed in prostate cancer cell lines, which was further corroborated by in vivo studies with mice that showed SPHK1 inhibition, smaller tumor volume, and reduced occurrence and number of metastases [34]. This evidence concerns the gene SPHK1 and prostate carcinoma.